Learn more about the announcement from Orphazyme, communicating the topline results from the Phase 2/3 trial of arimoclomol for...
Inclusion Body Myositis (IBM) is classified as a chronic, degenerative neuromuscular disease in which inflammatory cells invade muscle tissue causing progressive muscle weakness and wasting. IBM differs from other types of Myositis in that there is currently no known effective treatment for the disease.
IBM is known to cause slow, progressive asymmetrical weakness and atrophy of the muscles of the wrists and fingers, muscles in the front of the thigh, and muscles that lift the front of the foot. Patients who have the disease can gradually lose the ability to walk, experience falls and injuries, lose hand function, and have swallowing difficulties. Some patients also experience muscle pain.
The first muscles affected in Inclusion Body Myositis are usually those of the wrists and fingers, and the muscles at the front of the thigh. The muscles that lift the front of the foot also may be affected (see image to the right).
Muscle weakness is often asymmetrical, more prominent on one side than the other.
AllStripes provides an update on the inclusion body myositis (IBM) research program and the video includes a step-by-step walkthrough...
Clinical Trial of Arimoclomol in Inclusion Body Myositis during the COVID-19 Pandemic
Myositis Support, , Featured, Inclusion Body Myositis (IBM), NewsInformation from Orphazyme A/S about the Clinical Development of Arimoclomol in sIBM during the COVID-19 Pandemic. Read a statement...
Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis
Myositis Support, , Featured, Inclusion Body Myositis (IBM)Orphazyme's Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis, an incurable rare progressively debilitating muscle-wasting disease...
Summary of Dysphagia in patients with sporadic inclusion body myositis: Management challenges
Myositis Support, , Featured, Inclusion Body Myositis (IBM)A summary of the review, including Coping Strategies provided by MSU International Science Advisor and IBM patient, Bill Tillier....
Announcing the Mary Jane DeLauder Memorial Fund for inclusion body myositis
Myositis Support, , Featured, Inclusion Body Myositis (IBM), News, PressMary Jane's passion for welcoming and educating was well-known throughout the myositis community. That’s why we can think of...
Join the Yale Inclusion Body Myositis Registry
Myositis Support, , Featured, Inclusion Body Myositis (IBM)The success of the Registry effort depends on the cooperative efforts of IBM patients around the world. The IBM...
Watch the AllStripes, formerly RDMD, video session we did in 2020 to learn more about the Inclusion Body Myositis...
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for Sporadic Inclusion Body Myositis Video
Myositis Support, , Featured, Inclusion Body Myositis (IBM)The ongoing Arimoclomol Clinical Trial for sIBM continues to generate a lot of questions from our community. As part...
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for sIBM
Myositis Support, , Inclusion Body Myositis (IBM), VideoWatch "An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for sIBM" with Dr. Mazen Dimachkie,...
RDMD and MSU Collaborating for IBM Research
Myositis Support, , Featured, Inclusion Body Myositis (IBM), NewsWe are excited to announce a new collaboration with RDMD, a company that aims to jumpstart research for patients...
Advances in the Early Diagnosis and Therapy of Inclusion Body Myositis
Myositis Support, , Featured, Inclusion Body Myositis (IBM)The purpose of this article is to describe advancements in the diagnosis of Inclusion Body Myositis (IBM) and therapy...
New Study for Patients with Inclusion Body Myositis (IBM) at Yale
Myositis Support, , Inclusion Body Myositis (IBM)We would like to let you know about a clinical research study that is available for patients diagnosed with...
New Insights on sporadic Inclusion body myositis (sIBM) pathogenesis
Myositis Support, , Inclusion Body Myositis (IBM), News, VideoDr. Conrad "Chris" Weihl joins MSU live for a session titled "New Insights on sporadic Inclusion body myositis (sIBM)...
The NT5C1A Antibody Test and its Role in the Diagnosis of Inclusion Body Myositis
Myositis Support, , Inclusion Body Myositis (IBM), VideoLearn more about the NT5CIA antibody and its association with inclusion body myositis from Dr. Kevin Dooley, a retired...
Orphazyme formally assumes the sponsorship of Phase II/III arimoclomol trial for sIBM
Myositis Support, , Inclusion Body Myositis (IBM), NewsOn December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme formally assumes the...
FDA grants Orphazyme drug arimoclomol orphan drug designation in the U.S.
Myositis Support, , Inclusion Body Myositis (IBM), NewsOrphazyme A/S, a Danish biotech company with a late-stage orphan drug pipeline, today announced that the U.S. Food and...
Sadly, my mum lost her battle as an IBM warrior
Myositis Support, , Inclusion Body Myositis (IBM), Personal StoriesMums journey was a very difficult one. I remember her first fall the day I gave birth to...
Inclusion body myositis (IBM) is a rare muscle disease which is characterized by chronic muscle inflammation and weakness. Unlike...